Logo image of ICCM

ICECURE MEDICAL LTD (ICCM) Stock Fundamental Analysis

NASDAQ:ICCM - Nasdaq - IL0011224156 - Common Stock - Currency: USD

1.01  -0.01 (-0.98%)

After market: 1.01 0 (0%)

Fundamental Rating

3

Overall ICCM gets a fundamental rating of 3 out of 10. We evaluated ICCM against 187 industry peers in the Health Care Equipment & Supplies industry. ICCM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ICCM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ICCM has reported negative net income.
In the past year ICCM has reported a negative cash flow from operations.
ICCM had negative earnings in each of the past 5 years.
ICCM had a negative operating cash flow in each of the past 5 years.
ICCM Yearly Net Income VS EBIT VS OCF VS FCFICCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

ICCM's Return On Assets of -137.76% is on the low side compared to the rest of the industry. ICCM is outperformed by 87.70% of its industry peers.
The Return On Equity of ICCM (-254.95%) is worse than 77.54% of its industry peers.
Industry RankSector Rank
ROA -137.76%
ROE -254.95%
ROIC N/A
ROA(3y)-89.11%
ROA(5y)-66.89%
ROE(3y)-136.41%
ROE(5y)-102.39%
ROIC(3y)N/A
ROIC(5y)N/A
ICCM Yearly ROA, ROE, ROICICCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800 1K

1.3 Margins

ICCM has a Gross Margin of 42.77%. This is in the lower half of the industry: ICCM underperforms 64.17% of its industry peers.
In the last couple of years the Gross Margin of ICCM has grown nicely.
ICCM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.03%
GM growth 5Y4.86%
ICCM Yearly Profit, Operating, Gross MarginsICCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

5

2. Health

2.1 Basic Checks

ICCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ICCM has more shares outstanding
The number of shares outstanding for ICCM has been increased compared to 5 years ago.
There is no outstanding debt for ICCM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ICCM Yearly Shares OutstandingICCM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ICCM Yearly Total Debt VS Total AssetsICCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -10.59, we must say that ICCM is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.59, ICCM is doing worse than 81.82% of the companies in the same industry.
ICCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.59
ROIC/WACCN/A
WACC9.07%
ICCM Yearly LT Debt VS Equity VS FCFICCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

ICCM has a Current Ratio of 1.89. This is a normal value and indicates that ICCM is financially healthy and should not expect problems in meeting its short term obligations.
ICCM's Current ratio of 1.89 is on the low side compared to the rest of the industry. ICCM is outperformed by 67.38% of its industry peers.
ICCM has a Quick Ratio of 1.48. This is a normal value and indicates that ICCM is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.48, ICCM perfoms like the industry average, outperforming 41.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.48
ICCM Yearly Current Assets VS Current LiabilitesICCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

6

3. Growth

3.1 Past

ICCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.26%, which is quite good.
Looking at the last year, ICCM shows a small growth in Revenue. The Revenue has grown by 0.34% in the last year.
The Revenue has been growing by 15.37% on average over the past years. This is quite good.
EPS 1Y (TTM)10.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)0.34%
Revenue growth 3Y-7.36%
Revenue growth 5Y15.37%
Sales Q2Q%-2.42%

3.2 Future

ICCM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.30% yearly.
The Revenue is expected to grow by 90.27% on average over the next years. This is a very strong growth
EPS Next Y27.47%
EPS Next 2Y19.72%
EPS Next 3Y30.8%
EPS Next 5Y25.3%
Revenue Next Year69.88%
Revenue Next 2Y95.49%
Revenue Next 3Y139.27%
Revenue Next 5Y90.27%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ICCM Yearly Revenue VS EstimatesICCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M 100M
ICCM Yearly EPS VS EstimatesICCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.2 -0.2 0.4 -0.4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ICCM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ICCM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICCM Price Earnings VS Forward Price EarningsICCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICCM Per share dataICCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as ICCM's earnings are expected to grow with 30.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.72%
EPS Next 3Y30.8%

More info and screens

0

5. Dividend

5.1 Amount

ICCM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ICECURE MEDICAL LTD

NASDAQ:ICCM (8/1/2025, 8:00:02 PM)

After market: 1.01 0 (0%)

1.01

-0.01 (-0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-28 2025-05-28/bmo
Earnings (Next)08-04 2025-08-04
Inst Owners0.22%
Inst Owner Change21.21%
Ins Owners47.55%
Ins Owner ChangeN/A
Market Cap59.29M
Analysts82.22
Price Target3.07 (203.96%)
Short Float %1.16%
Short Ratio0.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.95%
Min EPS beat(2)-4.58%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)8.32%
Min EPS beat(4)-4.58%
Max EPS beat(4)26.47%
EPS beat(8)6
Avg EPS beat(8)7.37%
EPS beat(12)9
Avg EPS beat(12)6.56%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.44%
Min Revenue beat(2)-19.65%
Max Revenue beat(2)-5.23%
Revenue beat(4)1
Avg Revenue beat(4)-6.54%
Min Revenue beat(4)-19.65%
Max Revenue beat(4)7.1%
Revenue beat(8)2
Avg Revenue beat(8)-13.6%
Revenue beat(12)2
Avg Revenue beat(12)-15.41%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.13%
EPS NQ rev (1m)-8.33%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)20%
Revenue NQ rev (1m)-26.43%
Revenue NQ rev (3m)-32.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.11
P/FCF N/A
P/OCF N/A
P/B 9.88
P/tB 9.88
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.17
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.06
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -137.76%
ROE -254.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.77%
FCFM N/A
ROA(3y)-89.11%
ROA(5y)-66.89%
ROE(3y)-136.41%
ROE(5y)-102.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.03%
GM growth 5Y4.86%
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.58%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.48
Altman-Z -10.59
F-Score4
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)175.33%
Cap/Depr(5y)260.07%
Cap/Sales(3y)15.28%
Cap/Sales(5y)12.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y27.47%
EPS Next 2Y19.72%
EPS Next 3Y30.8%
EPS Next 5Y25.3%
Revenue 1Y (TTM)0.34%
Revenue growth 3Y-7.36%
Revenue growth 5Y15.37%
Sales Q2Q%-2.42%
Revenue Next Year69.88%
Revenue Next 2Y95.49%
Revenue Next 3Y139.27%
Revenue Next 5Y90.27%
EBIT growth 1Y-2.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.94%
OCF growth 3YN/A
OCF growth 5YN/A